Pfizer’s COVID-19 vaccine trial data shows long-term efficacy

Pfizer’s COVID-19 vaccine
Pfizer said on Monday its COVID-19 vaccine provided strong long-term protection against the virus in a late-stage study conducted among adolescents aged 12 to 15 years.

A two-dose series of the vaccine was 100% effective against COVID-19, measured seven days through over four months after the second dose, the company said.

The long-term data will support planned submissions for full-regulatory approval of the vaccine in the age group in the United States and worldwide.

Pfizer and BioNTech will seek clearance for a 30 micrograms dose of the vaccine for those aged 12 and above.

The vaccine was authorized for emergency use in people aged 12-15 years by the U.S. Food & Drug Administration in May, and granted full approval for use in people aged 16 and above in August.



from latest-news - SUCH TV https://ift.tt/3FFnxyl

Comments

Popular posts from this blog

Low payments by fed govt hampered development in Sindh, CM Murad tells Bilawal Bhutto

Six more die in rain-related incidents in Karachi

Four soldiers martyred in gun battle with terrorists in North Waziristan: ISPR

Joint Opposition to move no-confidence motion against NA Speaker Asad Qaiser

Former PM's close aide Shahzad Akbar's name placed on ECL

CPEC extend to Afghanistan says China

Saudi princess freed after three years in jail

New on Sports Illustrated: Forde-Yard Dash: The SEC is Unrecognizable as Defenses Underwhelm

Pakistan rejects illegal grant of IOK domicile certificates to Indians

Lahore Qalandars beat Peshawar Zalmi by 4 wickets in PSL 6